Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.

Stéphane TerryCécile DalbanNathalie Rioux-LeclercqJulien AdamMaxime MeylanStéphanie BuartAntoine BougoüinAlexandra LespagnolFrédéric DugayIrelka Colina MorenoGuillaume LacroixJames B LorensGro GausdalWolf H FridmanFathia Mami-ChouaibNathalie ChaputBenoit BeuselinckSylvie ChabaudJanice Barros-MonteiroYann VanoBernard EscudierCatherine Sautès-FridmanLaurence AlbigesSalem Chouaib

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Our findings propose AXL as candidate factor of resistance to PD-1 blockade, and provide compelling support for screening both AXL and PD-L1 expression in the management of advanced ccRCC.

Keyphrases

tyrosine kinase
renal cell carcinoma